60 Degrees Pharmaceuticals, Inc. (SXTP) · Nov 6, 2026 · Share issuance
$526K warrant exercise — 584,492 shares exercised at $0.90; 1,168,984 new warrants
60 Degrees Pharmaceuticals’ warrant financing brings in $526K gross, but the cash comes with a sharp repricing and 1.17M new warrants.
60 Degrees Pharmaceuticals is a cash-constrained specialty drug company commercializing Arakoda for malaria prevention while funding a babesiosis treatment program aimed at a future supplemental FDA approval. Its June 2026 filing showed $1.02 million of cash, $4.97 million of operating cash burn in six months, and substantial doubt about continuing as a going concern; the company’s pipeline remains dependent on repeated equity financing.
The immediate benefit is real but small: warrant holders agreed to exercise 584,492 existing warrants for $526,042.80 of gross cash, which the company plans to use for working capital and general corporate purposes. Against the company’s prior cash needs, this is a liquidity bridge—not funding that materially changes the operating story.
The financing terms are notably expensive: existing warrant exercise prices ranging from $7.60 to $27.60 are being cut to $0.90, while investors receive new warrants covering twice as many shares as the warrants they exercise. This secures cash now, but makes future dilution substantially heavier and signals that capital providers had strong negotiating leverage.
The event helps survival more than it advances the business: the company also pays H.C. Wainwright 8.5% of gross proceeds in cash, $10,000 of expenses, and warrants for up to 43,837 additional shares at $1.125. The new warrants cannot be exercised until stockholder approval, with the company required to keep seeking approval every 90 days if needed, so the full dilution is deferred but not removed.
| Transaction | Existing terms | New terms | |
|---|---|---|---|
| Warrant shares exercised (Item 1.01) | 584,492 | — | $0.90 |
| Gross proceeds (Item 1.01) | $526,042.80 | — | — |
| New warrant shares (Item 1.01) | 1,168,984 | — | 200% of exercised shares |
| Exercise price (Item 1.01) | $0.90 | $7.60–$27.60 | $0.90 |
| Placement-agent warrants (Item 1.01) | 43,837 | — | $1.125 |
Bottom line: This buys 60 Degrees Pharmaceuticals limited operating time, but only by accepting a highly dilutive repricing that weakens the quality of the financing. It modestly supports near-term liquidity while reinforcing—not resolving—the company’s dependence on repeated capital raises.
Stockholder vote on new warrant issuance within 90 days
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!